FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer

On November 16, 2026 Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), reported that the United States (U.S.) Food and Drug Administration (FDA) has approved WILSERDLY (giredestrant) in combination with everolimus for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The approval of WILSERDLY addresses an important unmet need for patients developing resistance. Up to 40% of patients with hormone receptor (HR)-positive metastatic breast cancer develop ESR1 mutations that drive resistance and disease progression. WILSERDLY plus everolimus addresses this by targeting two different signaling pathways while helping to minimize the impact of treatment on people’s lives as an oral regimen without the need for injections.

"For patients with ESR1-mutated advanced breast cancer, the development of resistance to endocrine therapy remains a substantial challenge — often requiring more intensive treatment," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "By pairing potent estrogen receptor degradation with everolimus, WILSERDLY offers a targeted, all-oral regimen that significantly delays disease progression and allows advanced breast cancer patients to take their treatment from home."

The FDA approval is supported by positive primary endpoint data from the Phase III evERA Breast Cancer study published in The New England Journal of Medicine. In adult patients with ESR1-mutated, ER-positive, HER2-negative locally advanced or metastatic breast cancer progressing after prior cyclin-dependent kinase (CDK)4/6 inhibitor therapy, the all-oral combination of WILSERDLY plus everolimus significantly prolonged progression-free survival, achieving a 62% reduction in the risk of disease progression or death compared to standard endocrine therapy plus everolimus (stratified hazard ratio=0.38; 95% confidence interval: 0.27–0.54; p<0.0001).

"Patients with advanced breast cancer progressing on endocrine therapies often face difficult choices and deteriorating quality of life as options narrow," said Dr. Erica L. Mayer, director of breast cancer clinical research at the Dana-Farber Cancer Institute. "The evERA trial demonstrates that the oral giredestrant combination regimen directly targets the primary genomic drivers of resistance, offering patients prolonged disease control through a fully oral therapeutic option."

"For more than three decades, Genentech has transformed care across oncology, and this first approval for WILSERDLY marks a pivotal leap forward in addressing aggressive, treatment-resistant breast cancer," said Teresa Graham, chief executive officer, Roche Pharmaceuticals. "We remain focused on maximizing the clinical impact of WILSERDLY across the continuum of care, including early-stage disease."

Genentech has also submitted a New Drug Application for WILSERDLY as an adjuvant treatment for adults with ER-positive, HER2-negative, stage I, II, and III breast cancer at intermediate to high risk of recurrence based on the Phase III lidERA Breast Cancer study, which was accepted under Priority Review. The FDA has set a Prescription Drug User Fee Act date of November 30, 2026. If approved, this would represent the first new adjuvant endocrine therapy in over 20 years, with potential to establish a new standard of care in this setting.

Genentech’s broad and robust WILSERDLY clinical development program spans distinct treatment settings and lines of therapy, reflecting our commitment to deliver innovative medicines to as many people with HR-positive breast cancer as possible. Additional regulatory filings and development activities are underway in markets outside the U.S.

U.S. Availability and Access

WILSERDLY is expected to be available in the U.S. in the coming weeks. Through Genentech Access Solutions, patients and healthcare providers can receive support navigating insurance coverage, understanding reimbursement options and identifying potential financial assistance. Eligible patients with commercial insurance may pay as little as $0 for WILSERDLY through Genentech’s co-pay assistance program. For patients experiencing documented insurance-related delays, the WILSERDLY Bridge Program may offer temporary, free Genentech-supplied medication to help eligible patients start treatment while coverage is being resolved. For more information, please call (866) 4ACCESS/(866) 422-2377 or go to View Source

For more information on WILSERDLY, visit View Source or call 1-844-WILSERDLY / 1-844-945-7373.

About the evERA Breast Cancer study

evERA Breast Cancer [NCT05306340] is a Phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of WILSERDLY (giredestrant) in combination with everolimus versus standard endocrine therapy in combination with everolimus in people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase (CDK)4/6 inhibitor and endocrine therapy, either in the adjuvant or locally advanced/metastatic setting.

The co-primary endpoints are investigator-assessed progression-free survival in the intention-to-treat and ESR1-mutated populations, defined as the time from randomization to the time when the disease progresses or a patient dies from any cause. Approximately 40% of people with HR-positive metastatic breast cancer who received first-line endocrine therapy have ESR1 mutations. Key secondary endpoints include overall survival, objective response rate, duration of response, clinical benefit rate and safety.

About WILSERDLY (giredestrant)

WILSERDLY is a next-generation, potent, oral selective estrogen receptor degrader (SERD) and full antagonist designed to achieve deep and sustained inhibition of estrogen receptor (ER) signaling. WILSERDLY is designed to block estrogen from binding to the ER, triggering the breakdown of the ER protein (known as degradation) and stopping or slowing down the growth of cancer cells.

Key mechanisms of resistance to a cyclin-dependent kinase (CDK)4/6 inhibitor and endocrine therapy include activation of the PAM (PI3K/AKT/mTOR) signaling pathway while maintaining dependency on ER. WILSERDLY’s antiproliferative activity is synergistically enhanced when combined with an mTOR inhibitor, addressing a key resistance mechanism.

Pre-clinical data have demonstrated improved clinical potency versus other oral SERDs, potentially enabling treatment at one of the lowest doses among oral SERDs.

WILSERDLY has an extensive clinical development program including six company-sponsored Phase III clinical trials across multiple treatment settings and lines of therapy:

Study

Intervention

Patient population

Positive primary study readouts completed

lidERA Breast Cancer; NCT04961996

WILSERDLY versus standard endocrine therapy as adjuvant treatment

ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer

evERA Breast Cancer; NCT05306340

WILSERDLY plus everolimus versus standard endocrine therapy plus everolimus

ER-positive, HER2-negative, locally advanced or metastatic breast cancer

Primary study readouts pending

pionERA Breast Cancer; NCT06065748

WILSERDLY plus investigator’s choice of a cyclin-dependent kinase (CDK)4/6 inhibitor versus fulvestrant plus an investigator’s choice CDK4/6 inhibitor

ER-positive, HER2-negative advanced breast cancer resistant to adjuvant endocrine therapy

heredERA Breast Cancer; NCT05296798

WILSERDLY plus dual HER2 blockade versus dual HER2 blockade plus optional standard endocrine therapy at investigator’s discretion

ER-positive, HER2-positive locally advanced or metastatic breast cancer

novERA Breast Cancer; NCT07541079

WILSERDLY, evaluating adherence, tolerability, and patient-reported outcomes

Patients with ER-positive, HER2-negative early-stage breast cancer who are intolerant to adjuvant aromatase inhibitor treatment

kalitERA; NCT07827573

WILSERDLY, evaluating treatment adherence, tolerability, and patient-reported outcomes

ER-positive, HER2-negative early-stage breast cancer

About hormone receptor (HR)-positive breast cancer

Globally, the burden of breast cancer continues to grow, with 2.3 million women diagnosed and 670,000 dying from the disease every year. Breast cancer remains the number one cause of cancer-related deaths amongst women, and the second most common cancer type.

HR-positive, human epidermal growth factor receptor 2-negative breast cancer accounts for approximately 70% of breast cancer cases and more than 90% are diagnosed in the early-stage. A defining feature of HR-positive breast cancer is that its tumor cells have receptors that attach to hormones like estrogen, which can contribute to tumor growth.

Despite treatment advances, HR-positive breast cancer remains particularly challenging to treat due to its biological complexity. Patients often face the risk of disease progression, treatment side effects and resistance to endocrine therapy. There is an urgent need for more effective treatments that can delay clinical progression and reduce the burden of treatment on people’s lives.

What is WILSERDLY?

WILSERDLYTM (giredestrant) is a prescription medicine used, in combination with the medicine everolimus, to treat adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), breast cancer that has a certain estrogen receptor (ESR1) gene mutation and has spread to nearby tissue or lymph nodes (locally advanced) or to other parts of the body (metastatic) whose cancer:

has come back during or after finishing hormone (endocrine) treatment given after surgery (adjuvant therapy)
OR

has worsened after at least one type of endocrine treatment for metastatic cancer.

Your healthcare provider will perform a test to make sure that WILSERDLY is right for you.

It is not known if WILSERDLY is safe and effective in children.

Important: WILSERDLY is used with everolimus. You should also read the Patient Information that comes with everolimus.

What are the possible side effects of WILSERDLY?

WILSERDLY can cause serious side effects, including:

Slow heart rate (bradycardia). WILSERDLY can cause your heart rate to slow down. Your healthcare provider will monitor your heart rate more frequently if you have a history of slow heart rate or take certain heart medicines. Tell your healthcare provider if you develop any signs and symptoms of a slow heart rate, including:
dizziness
lightheadedness
fainting
shortness of breath
chest pain
tiredness

The most common side effects and abnormal blood test results of WILSERDLY in combination with everolimus include:

decreased red blood cell counts
decreased white blood cell counts
increased liver enzymes (aspartate aminotransferase [AST] and alanine aminotransaminase [ALT])
mouth sores (stomatitis)
decreased platelet counts
decreased calcium blood levels
decreased potassium blood levels
rash
increased creatinine blood levels (kidney function test)
tiredness
decreased sodium blood levels
diarrhea
muscle and joint pain
lung or breathing problems
nausea

WILSERDLY may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects of WILSERDLY.

Before taking WILSERDLY, tell your healthcare provider about all of your medical conditions, including if you:

have a slow heart rate (bradycardia)
are pregnant or plan to become pregnant. WILSERDLY can harm your unborn baby
Females who are able to become pregnant:
Your healthcare provider will do a pregnancy test before you start treatment with WILSERDLY.
Use effective non-hormonal birth control (contraception) during treatment with WILSERDLY, and for 2 weeks after the last dose of WILSERDLY. Talk to your healthcare provider about birth control methods that may be right for you.
Tell your healthcare provider right away if you become pregnant during treatment with WILSERDLY or think you may be pregnant.
Males with female partners who are able to become pregnant:
Use effective birth control (contraception) during treatment with WILSERDLY, and for 2 weeks after the last dose of WILSERDLY.
are breastfeeding or plan to breastfeed. It is not known if WILSERDLY passes into your breast milk. Do not breastfeed during treatment with WILSERDLY and for 2 weeks after the last dose of WILSERDLY. Talk to your healthcare provider about the best way to feed your baby during this time.
have an intolerance to some sugars found in milk and milk products. WILSERDLY capsules contain lactose monohydrate.

Tell your healthcare provider about all the medicines you take, including prescription medicines, and over-the-counter medicines, vitamins, and herbal supplements. Taking WILSERDLY with certain other medicines may affect how WILSERDLY works and may cause side effects. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What should I avoid while taking WILSERDLY?

Avoid eating grapefruit and drinking grapefruit juice during treatment with WILSERDLY. Grapefruit may increase the amount of WILSERDLY in your blood.

Talk to your healthcare provider for more information about the benefits and risks of WILSERDLY.

You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see Important Safety Information as well as the WILSERDLY full Prescribing Information and Patient Information.

(Press release, Genentech, NOV 16, 2026, View Source [SID1234674813])

Akeso Announces NMPA Acceptance of sNDA for Ivonescimab in Combination with Chemotherapy for First-Line Biliary Tract Cancer

On November 16, 2026 Akeso, Inc. (9926.HK) ("Akeso" or the "Company") reported that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for ivonescimab in combination with chemotherapy for the first-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC). The application was previously granted Priority Review designation by the NMPA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This acceptance marks the fourth marketing application submitted for ivonescimab in China and represents the first expansion of ivonescimab’s clinical development into gastrointestinal cancers beyond its established lung cancer indications.

The sNDA is supported by results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-GI1 study (AK112-309). The study evaluated ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy, a current global standard of care for first-line BTC. At a pre-specified interim analysis, the study met its primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement. All key secondary endpoints, including progression-free survival (PFS) and objective response rate (ORR), were also met.

HARMONi-GI1 is the first Phase III study in biliary tract cancer to demonstrate a statistically significant overall survival benefit versus a PD-L1 inhibitor plus chemotherapy regimen. The results were presented as a Late-Breaking Abstract in an oral presentation at the ESMO (Free ESMO Whitepaper) Presidential Symposium in October 2026.

Key efficacy findings from the HARMONi-GI1 study include:

Median overall survival: 14.9 months for the ivonescimab group versus 12.1 months for the durvalumab group (HR 0.75; P=0.0031)
Median progression-free survival: 8.4 months for the ivonescimab group versus 5.8 months for the durvalumab group (HR 0.61; P<0.0001)
Objective response rate: 53.8% for the ivonescimab group versus 32.5% for the durvalumab group
The global registrational development of ivonescimab in biliary tract cancer is progressing. The Phase II/III study EA2251, conducted in collaboration with Summit Therapeutics, and the ECOG-ACRIN Cancer Research Group, has been initiated. This study will evaluate ivonescimab plus chemotherapy versus pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of advanced BTC. EA2251 represents the seventh international registrational clinical trial of ivonescimab.

(Press release, Akeso Biopharma, NOV 16, 2026, View Source [SID1234674830])

European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

On November 16, 2026 Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, reported that the European Commission (EC) has approved RASONQUE (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.1 RASONQUE, given once daily as oral tablets, is approved for adults with metastatic pancreatic adenocarcinoma with or without an identified RAS tumor mutation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For decades, physicians treating metastatic pancreatic cancer have had limited options beyond cytotoxic chemotherapy, underscoring the urgent need for new therapeutic approaches," said Dr. Thomas Seufferlein, medical director, Clinic for Internal Medicine I, Ulm University Hospital. "The European Commission’s approval of daraxonrasib represents an important advance for patients with this aggressive and difficult-to-treat disease. The unprecedented survival benefit demonstrated in the RASolute 302 clinical trial underscores the potential of daraxonrasib to establish a new standard of care for eligible patients with metastatic pancreatic cancer across the European Union."

"Today’s European Commission approval of RASONQUE represents a pivotal moment for people in the European Union living with metastatic pancreatic cancer, as well as their families," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "With RASONQUE now approved, we are actively working with healthcare systems and stakeholders across the region to support timely access for eligible patients. We also continue to engage with regulatory authorities around the world with the goal of expanding and accelerating the reach of RASONQUE to patients who may benefit from it."

The approval by the EC follows the positive opinion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), which was part of an expedited phased review under the EMA’s Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need.

The EC approval is based on results from the Phase 3 RASolute 302 clinical trial, presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and simultaneously published in The New England Journal of Medicine. RASolute 302 was a global, randomized Phase 3 trial evaluating RASONQUE versus investigator’s choice of cytotoxic chemotherapy in patients with previously treated metastatic PDAC. The trial met all primary and key secondary endpoints in both the RAS G12 mutant population and the overall intent-to-treat (ITT) population, which included patients with or without an identified tumor RAS mutation.

The EC has granted marketing authorization for RASONQUE in all European Union member states as well as the European Economic Area (EEA) countries Iceland, Norway, and Liechtenstein. This marketing authorization does not apply in the United Kingdom or Switzerland, which have separate regulatory approval processes.

Revolution Medicines is working closely with reimbursement and assessment bodies in European Union countries to enable broad and rapid access to patients in need. Timing of patient access will vary by country and depends on completion of national pricing, health-technology assessment and reimbursement processes.

About Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma, or PDAC, is the most common form of pancreatic cancer and among the most lethal malignancies, frequently with a late diagnosis, aggressive biology, and limited responsiveness to conventional treatments. RAS, a key growth control switch in human cells, is the main driver of pancreatic cancer, which is characterized by excessive RAS signaling. Approximately 147,000 people are diagnosed with pancreatic cancer in Europe each year, and the five-year survival rate remains below 10%.2,3 Because early-stage pancreatic cancer often causes few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread, when treatment options are more limited.4

About RASONQUETM (daraxonrasib)

RASONQUE (daraxonrasib) is an oral, RAS(ON) multi-selective, noncovalent, tri-complex inhibitor (TCI), approved by the U.S. FDA for the treatment of adult patients with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy, and granted marketing authorization by the EC for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.1,5 RASONQUE is being investigated through global Phase 3 registrational trials in patients with PDAC and metastatic RAS mutant non-small cell lung cancer (NSCLC).

About the RASolute 302 Clinical Trial

RASolute 302 (NCT06625320) was a global, randomized Phase 3 registrational clinical trial designed to evaluate the efficacy and safety of RASONQUE as a monotherapy in patients with previously treated metastatic pancreatic adenocarcinoma (PDAC). In the trial, patients were randomized to receive either an oral dose of 300 mg RASONQUE once daily or investigator’s choice of four different cytotoxic chemotherapy regimens, which represented standard of care across the globe. The trial enrolled patients with metastatic PDAC harboring a wide range of RAS variants, including those with RAS G12 mutations (such as G12D, G12V, and G12R), as well as patients without an identified tumor RAS mutation (wild-type).

The primary endpoints of the RASolute 302 trial were progression-free survival (PFS), as assessed by a Blinded Independent Central Review according to RECIST 1.1, and overall survival (OS) in patients with tumors harboring RAS G12 mutations. Secondary endpoints included PFS and OS in all enrolled patients (the intent-to-treat population) encompassing patients with and without identified tumor RAS mutations, as well as objective response rate, duration of response, and patient-reported quality of life.

EU Indication

RASONQUE as monotherapy is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

U.S. INDICATION

RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

U.S. IMPORTANT SAFETY INFORMATION

RASONQUE is associated with the following Warnings and Precautions: Dermatologic and Soft Tissue Toxicity, Stomatitis and Oral Disorders, Diarrhea, Gastrointestinal Perforation, Interstitial Lung Disease (ILD)/Pneumonitis, and Embryo-Fetal Toxicity.

U.S. WARNINGS AND PRECAUTIONS

Dermatologic and Soft Tissue Toxicity

RASONQUE can cause dermatologic toxicity, which may be severe. Clinical manifestations included, but were not limited to, rash, pruritus, paronychia, dry skin, and skin fissures. In clinical trials of patients with pancreatic adenocarcinoma, dermatologic toxicity occurred in 86% of patients treated with RASONQUE, of which 10% were Grade 3.

Monitor patients who develop dermatologic or soft tissue toxicities while receiving RASONQUE. Initiate prophylactic measures (e.g., topical corticosteroids, emollient creams, sunscreen, oral antibiotics) prior to the first dose of RASONQUE to reduce the risk of moderate to severe dermatologic reactions. Advise patients to limit sun exposure while taking RASONQUE. Initiate supportive measures (e.g., oral corticosteroids) as clinically indicated, and consider dermatologic consultation. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Stomatitis and Oral Disorders

RASONQUE can cause stomatitis, including mouth ulcers and oral mucositis. In clinical trials of patients with pancreatic adenocarcinoma, stomatitis occurred in 57% of patients, of which 9% were Grade 3.

Monitor patients for signs and symptoms of stomatitis while receiving RASONQUE. Initiate a steroid-containing mouthwash for treatment of stomatitis and administer other topical treatments (e.g., chlorhexidine mouthwash, 2% lidocaine viscous) as clinically indicated. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Diarrhea

RASONQUE can cause diarrhea. In clinical trials of patients with pancreatic adenocarcinoma, diarrhea occurred in 63% of patients, of which 6% were Grade 3.

If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Withhold, reduce the dose, or permanently discontinue RASONQUE based on severity.

Gastrointestinal Perforation

RASONQUE can cause gastrointestinal perforation. In clinical trials of patients with pancreatic adenocarcinoma, gastrointestinal perforation occurred in 0.9% of patients treated with RASONQUE, of which 0.5% were Grade 3, one event was Grade 4, and one event was fatal.

Monitor patients for gastrointestinal perforation. Withhold RASONQUE if gastrointestinal perforation is suspected. Reduce the dose or permanently discontinue RASONQUE if no other potential causes of gastrointestinal perforation are identified.

Interstitial Lung Disease (ILD)/Pneumonitis

RASONQUE can cause interstitial lung disease or pneumonitis. In clinical trials of patients with pancreatic adenocarcinoma, ILD/pneumonitis occurred in 2.4% of patients treated with RASONQUE, of which 0.9% were Grade 3, and one event was fatal.

Monitor patients for new or worsening pulmonary symptoms. Withhold RASONQUE if ILD/pneumonitis is suspected. Reduce the dose or permanently discontinue RASONQUE if no other potential causes of ILD/pneumonitis are identified.

Embryo-Fetal Toxicity

Based on findings in animals, RASONQUE can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with RASONQUE and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with RASONQUE and for 1 week after the last dose.

ADVERSE REACTIONS

Serious adverse reactions occurred in 30% of patients treated with RASONQUE. Serious adverse reactions occurring in ≥ 2% of patients treated with RASONQUE were diarrhea (3.7%), pyrexia (3.3%), sepsis (2.9%), fatigue (2.1%), and hemorrhage (2.1%).

Adverse reactions leading to permanent discontinuation of RASONQUE occurred in 2.9% of patients, including two patients who discontinued due to rash (0.8%).

The most common (≥ 20%) adverse reactions in patients treated with RASONQUE were rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

DRUG INTERACTIONS

Strong CYP3A Inhibitors with P-gp Inhibition: Avoid concomitant use.
Strong CYP3A Inhibitors without P-gp Inhibition: Reduce RASONQUE dosage.
Moderate CYP3A Inhibitors with or without P-gp Inhibition: Reduce RASONQUE dosage.
P-gp Inhibitors: Reduce RASONQUE dosage.
Cyclosporine A: Avoid concomitant use.
Strong CYP3A Inducers: Avoid concomitant use. Increase RASONQUE dosage if concomitant use cannot be avoided.
Moderate CYP3A Inducers: Increase RASONQUE dosage.
P-gp Substrates: Take at least 4 hours apart from RASONQUE.


PROPHYLACTIC MEASURES

When initiating RASONQUE and throughout treatment, prophylactic and concomitant medications are recommended to reduce the risk of dermatologic reactions:

administer a topical corticosteroid (applied to the face and chest) and emollient creams
advise patients to limit sun exposure and use broad-spectrum sunscreen (SPF 30 or higher)
consider prophylactic oral antibiotics (e.g., doxycycline or minocycline)

Please see U.S. Full Prescribing Information for RASONQUE.

(Press release, Revolution Medicines, NOV 16, 2026, View Source [SID1234674814])

Rakuten Medical Initiates First-in-Human Phase 1 Trial of PD-L1-Targeted RM-0256 Photoimmunotherapy in Japan

On November 16, 2026 Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox platform-based photoimmunotherapy, reported that it has initiated a Phase 1 clinical trial of RM-0256 photoimmunotherapy in Japan. RM-0256, an anti-PD-L1 antibody-light-activatable dye conjugate, is the third drug candidate developed by Rakuten Medical based on its Alluminox platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study (RM-0256-101 / jRCT2031260118) is a first-in-human, open-label, non-controlled, dose-escalation trial that will enroll 24 patients with solid tumors, including malignant skin tumors, who are refractory to or ineligible for standard treatment. It is being conducted at Kobe University Hospital (Principal Investigator: Naomi Kiyota, M.D., Ph.D.), National Cancer Center Hospital (Principal Investigator: Noboru Yamamoto, M.D., Ph.D.), and National Cancer Center Hospital East (Principal Investigator: Akira Takahashi, M.D., Ph.D.).

The study is being funded by the Japan Agency for Medical Research and Development (AMED) to support the development of RM-0256 for advanced or recurrent malignant epithelial skin tumors, which are the initial target indication in this study.

The primary objectives of the study are to evaluate the safety and tolerability of RM-0256 photoimmunotherapy and to identify recommended drug and light doses for Phase 2 clinical development. Primary endpoints includes dose-limiting toxicities and adverse events. Secondary endpoints includes tumor response and pharmacokinetic parameters of RM-0256. Exploratory assessments will also evaluate biomarkers associated with RM-0256 photoimmunotherapy.

Background on PD-L1 and RM-0256
PD-L1 is an immune checkpoint protein expressed on tumor cells and on immunosuppressive cells in the tumor microenvironment, including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). The interaction of PD-L1 with PD-1 on activated T cells may suppress T-cell-mediated antitumor immune responses.

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway have become standard treatments for a variety of cancer types. However, there remains a need for novel treatment options for patients with highly immunosuppressed tumors or tumors that are resistant to ICIs.

RM-0256 is an antibody-dye conjugate comprising AB-256, a proprietary anti-PD-L1 monoclonal antibody developed by Rakuten Medical, and IRDye 700DX (IR700), a light-activatable dye. RM-0256 specifically binds to cells expressing PD-L1. In RM-0256 photoimmunotherapy, RM-0256 is administered intravenously, followed approximately 24 hours later by illumination of the targeted lesion with 690 nm laser light. The laser light transiently activates IR700, which, in preclinical studies, has been shown to induce necrosis or elimination of RM-0256-bound target cells.

Preclinical studies have suggested that RM-0256 photoimmunotherapy may act through three complementary mechanisms:

Elimination of PD-L1–expressing immunosuppressive cells;
Direct destruction of PD-L1-expressing tumor cells; and
Immune checkpoint blockade through inhibition of PD-L1/PD-1 interaction, potentially enhancing systemic antitumor immune responses.
About Alluminox platform
The Alluminox platform is Rakuten Medical’s investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical’s pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical’s Alluminox platform-based photoimmunotherapy is investigational.

(Press release, Rakuten Medical, NOV 16, 2026, View Source [SID1234674831])

Olema Oncology to Participate in Upcoming Investor Conferences

On November 17, 2026 Olema Oncology, Inc. ("Olema," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, reported that the Company will participate in the following upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

9th Annual Evercore Healthcare Conference
Date and Time: November 30, 2026 at 2:35 p.m. ET
Format: Fireside Chat
Location: Miami, FL

Citi’s 2026 Global Healthcare Conference
Date and Time: December 1, 2026 at 1:00 p.m. ET
Format: Fireside Chat
Location: Miami, FL

Piper Sandler 38th Annual Healthcare Conference
Date and Time: December 2, 2026 at 1:30 p.m. ET
Format: Fireside Chat
Location: New York, NY

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.

(Press release, Olema Oncology, NOV 16, 2026, View Source [SID1234674847])